Women with early-stage hormone receptor (HR)-positive breast cancer who had low to intermediate scores on the Oncotype DX Breast Recurrence Score assay did just as well on neoadjuvant endocrine ...

A retrospective study validates the Oncotype 21-gene breast recurrence score as a predictive biomarker of adjuvant chemotherapy benefit in women with estrogen receptor (ER)-positive/human epidermal ...

Please provide your email address to receive an email when new articles are posted on . Further study is needed to identify potential drivers of the association Low household income appeared ...

A new statistical tool that combines multiple clinical and pathologic factors with a patient's 21-gene Oncotype DX Breast Recurrence Score result provides more accurate estimates about that patient's ...

Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Positive Breast Cancer ...

Overall, 552 patients were tested and had RS 26–30 in the defined timeframe, of whom 18 were excluded from the current analysis. Eleven patients had no treatment or follow-up data, 3 had another ...

RECKGIST score effectively predicts recurrence in neurofibromatosis type 1-associated GISTs, especially for tumors under 30 mm. Larger GISTs (over 30 mm) have a higher risk of metastasis, with ...

Patients with early-stage estrogen receptor-positive breast cancer who live in low-income neighborhoods are likelier to have more aggressive tumors and significantly lower overall survival (OS) than ...

A new risk score can help predict which pancreatic cancer survivors are more likely to suffer a recurrence of their cancer, researchers said. The score could help better manage the follow-up care for ...

A new statistical tool that combines multiple clinical and pathologic factors with a patient's 21-gene Oncotype DX Breast Recurrence Score ® result provides more accurate estimates about that ...